Is Cosmax profitable in 2026?

Yes. Cosmax posted record FY2025 revenue of ₩2.3988 trillion (about $1.66B), up 10.7% YoY, with operating profit of ₩195.8 billion, up 11.6% YoY (2026-02-23). Q1 2026 revenue grew 15.9% YoY, but operating profit grew only 3.3%, signaling margin compression (2026-05-11).

Cosmax operates under a group structure: holding company Cosmax BTI holds 27.24% of Cosmax Inc as of Q1 2026. Within Cosmax BTI, Vice Chair and CEO Lee Byung-man became the largest shareholder with a 19.95% stake as of May 28, 2026, succeeding founder-family chair Seo Sung-seok.

Could AI replace Cosmax?

Unlikely soon. Cosmax's moat rests on proprietary formula libraries, CGMP/regulatory compliance infrastructure, and physical manufacturing serving ~5,000 client brands, none of which generic AI formulation tools (like L'Oréal and IBM's January 2025 model) can shortcut. Cosmax itself runs a CAI research center since 2021 and deploys AI internally rather than being disrupted by it.

Who is Cosmax's biggest competitor?

Kolmar Korea is Cosmax's closest peer ODM rival at comparable scale, also posting record 2025 results. Cosmecca Korea is the fastest riser, growing revenue 22.2% and operating profit 38.1% in FY2025 versus Cosmax's 10.7% and 11.6%, gaining ground as orders trickle down within Korea's ODM tier.

Has Cosmax had regulatory problems in the US?

Yes, historically. The FDA issued a warning letter dated October 15, 2020, citing CGMP violations, contamination, and glycerin-testing issues at Cosmax USA's Solon, Ohio sunscreen facility. No evidence of a current or ongoing enforcement action was found as of mid-2026.

Why did Cosmax's stock drop in 2025?

Cosmax shares fell roughly 40%, from a 2025 high of about ₩287,000 to around ₩174,100 by November 23, 2025, following an earnings disappointment (notably weaker Q3 2025 operating profit). Shares later rebounded, jumping 8.44% in a single July 2026 session on US-turnaround optimism.

Consumer brands · subsidiary of Cosmax BTI, Inc. (holding company; KRX: 044820) · South Korea

Cosmax Inc.

cosmax.com ↗

Korean ODM giant that manufactures cosmetics for thousands of brands worldwide.

Defensible for now

Assessed 25 July 2026 · Evidence as of 25 July 2026

Real protection, with named pressure against it.

On the recordSince 25 July 2026 · Checkable from August 11, 2026 · Every call on the record Checkpoint: Q2 2026 earnings release

The call

Cosmax keeps setting revenue and profit records, but margin compression and tighter competition from Kolmar and Cosmecca show the ODM business getting harder to run at the same returns.

Cosmax manufactures cosmetics and skincare products for over 5,000 beauty brands worldwide, handling everything from formula creation to bottling across six countries. Competitors like Kolmar Korea and Cosmecca are pressuring prices, and even though Cosmax has decades of experience, proprietary formulas, and regulatory know-how that rivals struggle to match quickly, a large customer could try making their own products to avoid the middleman. The real question is whether Cosmax can hold its profit margins steady while growing revenue, especially as it completes its acquisition of an Italian manufacturer and tries to turn around its U.S. business.

Why

AI pressure: L'Oreal's IBM-built AI formulation model. Brand owners could use AI formulation tools to cut reliance on ODM chemists, but they still need Cosmax's factories and regulatory approvals. Could AI do the core job? Unlikely.

Bigger players: Kolmar Korea and Cosmecca Korea. Rival ODMs compete hard on price and capacity, and Q1 2026 shows profit growing far slower than revenue as a result. Could a giant copy it? No, they are blocked.

What protects it. Proprietary formula libraries, regulatory approvals across markets, and a 5,000-brand client base make switching costly for customers.

What would change this call

Cosmax Q2 2026 earnings (~Aug 11, 2026) show operating profit growth vs revenue growth gap. Would show whether margin compression from Q1 2026 is worsening or stabilizing.
Any anchor brand client shifts significant production volume to Kolmar Korea or Cosmecca Korea. Would show peer ODMs are winning share, not just competing on price.
Keminova (Italy) acquisition receives or is denied Italian government approval. Would show whether Cosmax can expand its European manufacturing footprint as planned.

Key numbers

FY2025 revenue ₩2.3988T (~$1.66B), up 10.7% YoY (2026-02-23)
Q1 2026 revenue +15.9% but operating profit only +3.3% (2026-05-11)
Serves roughly 4,500 to 5,000 client brands globally (2026-01-14)

Named risks

Margin compression: Q1 2026 revenue +15.9% but operating profit only +3.3%. Severity: high
Stock volatility, down ~40% from 2025 high on earnings disappointment. Severity: medium
Faster-growing peer ODM Cosmecca eroding pricing power and share. Severity: medium
Historical FDA CGMP warning letter (2020) at US sunscreen facility, relevant given OTC drug manufacturing reliance. Severity: low
Keminova (Italy) acquisition pending government approval, completion unconfirmed. Severity: low

Rivals, as read in July 2026

Rival	Direction	Evidence
Kolmar Korea	contesting	Comparable-scale peer ODM, also posted record FY2025 results and joined large-conglomerate ranks (2026-05-13)
Cosmecca Korea	gaining on	FY2025 revenue +22.2% and OP +38.1% vs Cosmax's +10.7%/+11.6%, gaining share (2026-02-24)
L'Oréal (IBM AI formulation model)	contesting	Launched AI foundation model for cosmetic formulation for ~4,000 researchers, Jan 2025, but is a brand-owner tool not an ODM threat
C&C International	contesting	Korea's #4 ODM within the same ₩6T+ top-tier ODM cohort (2026-02-24)

Questions people ask

Is Cosmax profitable in 2026?: Yes. Cosmax posted record FY2025 revenue of ₩2.3988 trillion (about $1.66B), up 10.7% YoY, with operating profit of ₩195.8 billion, up 11.6% YoY (2026-02-23). Q1 2026 revenue grew 15.9% YoY, but operating profit grew only 3.3%, signaling margin compression (2026-05-11).
Who owns Cosmax?: Cosmax operates under a group structure: holding company Cosmax BTI holds 27.24% of Cosmax Inc as of Q1 2026. Within Cosmax BTI, Vice Chair and CEO Lee Byung-man became the largest shareholder with a 19.95% stake as of May 28, 2026, succeeding founder-family chair Seo Sung-seok.
Could AI replace Cosmax?: Unlikely soon. Cosmax's moat rests on proprietary formula libraries, CGMP/regulatory compliance infrastructure, and physical manufacturing serving ~5,000 client brands, none of which generic AI formulation tools (like L'Oréal and IBM's January 2025 model) can shortcut. Cosmax itself runs a CAI research center since 2021 and deploys AI internally rather than being disrupted by it.
Who is Cosmax's biggest competitor?: Kolmar Korea is Cosmax's closest peer ODM rival at comparable scale, also posting record 2025 results. Cosmecca Korea is the fastest riser, growing revenue 22.2% and operating profit 38.1% in FY2025 versus Cosmax's 10.7% and 11.6%, gaining ground as orders trickle down within Korea's ODM tier.
Has Cosmax had regulatory problems in the US?: Yes, historically. The FDA issued a warning letter dated October 15, 2020, citing CGMP violations, contamination, and glycerin-testing issues at Cosmax USA's Solon, Ohio sunscreen facility. No evidence of a current or ongoing enforcement action was found as of mid-2026.
Why did Cosmax's stock drop in 2025?: Cosmax shares fell roughly 40%, from a 2025 high of about ₩287,000 to around ₩174,100 by November 23, 2025, following an earnings disappointment (notably weaker Q3 2025 operating profit). Shares later rebounded, jumping 8.44% in a single July 2026 session on US-turnaround optimism.

Timeline

2026-07-01Cosmax reports AI robots on half of Pyeongtaek Plant 2 line, claims +40% productivity
2026-06-09FDA approves bemotrizinol, first new US sunscreen ingredient in about 25 years
2026-05-28Lee Byung-man becomes largest shareholder of Cosmax BTI with 19.95% stake
2026-05-11Q1 2026 revenue hits ₩682.0 billion, up 15.9% YoY, operating profit up only 3.3%
2026-02-26Cosmax adopts first-in-Korea robotic-arm ISO 23675:2024 SPF testing
2026-02-24Korea's top-4 ODMs combined post over ₩6 trillion FY2025 sales, up 11.5% YoY
2026-02-23Cosmax posts record FY2025 revenue ₩2.3988T and operating profit ₩195.8B
2026-02-22Cosmax signs agreement to acquire 51% of Italian ODM Keminova
2024-01Cosmax establishes OTC Lab targeting US sun care market
2020-10-15FDA issues CGMP warning letter to Cosmax USA's Solon, Ohio facility

Head to head

Cosmax Inc. vs Kolmar Korea Co., Ltd.

Revision history

25 July 2026

First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.

In the same band

Estée Lauder LVMH Moet Hennessy Louis Vuitton Chow Sang Sang Holdings International Limited